Corbus Pharmaceuticals Unveils Proposed Public Offering
Norwood, Mass. - Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a company dedicated to advancing treatments in oncology and obesity, has announced its intention to conduct an underwritten public offering. This offering will include shares of the company’s common stock and possibly pre-funded warrants to purchase common stock for specific investors. All securities offered will be issued by Corbus itself, although the timing and exact details of this offering will depend on market conditions.
Utilization of Proceeds from the Offering
Corbus has set forth plans to utilize the net proceeds from this public offering primarily to support the clinical development of its promising pipeline. This aligns with the company’s strategic goals of fostering innovation in the treatment of serious health conditions, alongside an allocation for general corporate purposes.
Management of the Offering
Leading investment firms Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for this offering. To further entice potential investors, Corbus intends to grant the underwriters a 30-day option to purchase an additional 15% of the common stock shares sold in this venture, allowing for greater flexibility and interest among investors.
Insights on Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. operates with a strong commitment to developing transformative therapies. Its portfolio boasts innovative treatments designed to target well-known biological pathways crucial in cancer and obesity treatment. Among its pipeline projects are CRB-701, which is an advanced antibody drug conjugate that zeroes in on cancer cells, CRB-601, an anti-integrin monoclonal antibody that interrupts TGF? activation on cancer cells, and CRB-913, aimed at obesity management.
Registration Information
A registration statement for the securities involved in this offering has been submitted to the Securities and Exchange Commission (SEC) and has received effective status. The initial prospectus supplement along with the base prospectus detailing the offering's terms will be filed with the SEC, offering potential investors clear insights into the opportunity at hand.
Company's Vision for Future
Corbus remains passionate about bringing innovative solutions to the market, striving to make a meaningful difference in the lives of patients battling serious diseases. Each initiative undertaken, including this public offering, unequivocally reflects the company’s dedication to advancing medical science and improving health outcomes.
Frequently Asked Questions
What is the purpose of Corbus Pharmaceuticals’ public offering?
The offering aims to raise funds for clinical development and general corporate purposes, enhancing the company's operational capacity.
Who is managing the offering?
Jefferies LLC and Piper Sandler & Co. are the joint book-running managers for this public offering.
What types of securities are being offered?
The offering will include common stock and, for specific investors, pre-funded warrants to purchase common stock.
How will the proceeds from the offering be used?
Proceeds will primarily fund clinical development of Corbus’ pipeline and support other general corporate needs.
What is Corbus Pharmaceuticals known for?
Corbus specializes in oncology and obesity, focusing on innovative clinical solutions that target well-understood biological pathways.
